CSIMarket
 
Atara Biotherapeutics Inc   (ATRA)
Other Ticker:  
 
 
Price: $10.4700 $0.32 3.153%
Day's High: $12.46 Week Perf: 31.53 %
Day's Low: $ 9.73 30 Day Perf: -25.49 %
Volume (M): 107 52 Wk High: $ 63.38
Volume (M$): $ 1,115 52 Wk Avg: $23.88
Open: $10.06 52 Wk Low: $4.97



 Market Capitalization (Millions $) 1,114
 Shares Outstanding (Millions) 106
 Employees -
 Revenues (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) -290
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 1

Atara Biotherapeutics Inc
Atara Biotherapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics to treat serious diseases, particularly rare and debilitating conditions. The company harnesses the power of the immune system to improve outcomes for patients with cancer, autoimmune diseases, and viral infections.

Atara Biotherapeutics specializes in developing T-cell immunotherapies, which involve modifying a patient's own immune cells to recognize and attack disease cells. One of the company's flagship product candidates is tabelecleucel (formerly known as ATA129), which is a T-cell immunotherapy being evaluated for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disorders (EBV+ PTLD) in patients who have undergone solid organ transplantation.

The company's pipeline also includes other potential therapies, such as ATA188, which is being developed for the treatment of progressive multiple sclerosis, as well as ATA3271, a mesothelin-targeted CAR T-cell therapy for the treatment of solid tumors.

Atara Biotherapeutics' mission is to transform the lives of patients with severe and life-threatening diseases by leveraging the potential of immunotherapy. They strive to bring innovative therapies to market to address significant unmet medical needs and improve patient outcomes.


   Company Address: 2380 Conejo Spectrum Street Thousand Oaks 91320 CA
   Company Phone Number: 623-4211   Stock Exchange / Ticker: NASDAQ ATRA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

ATA3219 CAR T Therapy: Atara Biotherapeutics New Frontier in Autoimmune Disease Treatm...

Published Wed, May 29 2024 10:38 PM UTC

'Atara Biotherapeutics Showcases Promising Preclinical Data for ATA3219 CAR T Therapy for Autoimmune Diseases at ISCT 2024'Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneering entity in T-cell immunotherapy, has released preclinical data that accentuates the potential of its latest therapy candidate, ATA3219, at the International Society for Cell & Gene Therapy (ISCT) 20...

Business Update

'Atara Biotherapeutics Pioneers a New Era in T-Cell Immunotherapy with Biologics License Application for Tabelecleucel

Published Mon, May 20 2024 1:41 PM UTC

'By Author Name''Published in CSIMarket.com ''Thousand Oaks, Calif.'??Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, has recently announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for their critical product, tabelecleucel (tab-cel). This significant milestone may pave the way for a...

Atara Biotherapeutics Inc

Atara Biotherapeutics Inc Reports Impressive Surge in Demand, Exceeding Expectations for July to September 30, 2023

tara Biotherapeutics Inc (ATRA) continues to navigate the highly competitive world of biotechnology and pharmaceuticals, the company's financial results for the July to September 30, 2023 fiscal interval have showcased encouraging signs. Notably, the company managed to decrease its loss per share and improve its income per share, while reporting a significant revenue increase. While challenges persist, Atara Biotherapeutics has remained steadfast in its commitment to research and strategic marketing efforts, as it seeks to overcome market hurdles and capitalize on future growth opportunities.
Positive Financial Highlights:
During the July to September 30, 2023 fiscal interval, Atara Biotherapeutics Inc posted a noteworthy improvement in its financial performance compared to the prior year. The company's loss per share decreased to $-0.66 from $-0.82, highlighting a positive trajectory. Additionally, its income per share witnessed an improvement, rising from $-0.68 to a more favorable figure.

Atara Biotherapeutics Inc

Atara Biotherapeutics Inc. Suffers Devastating Blow with -93.003% Decline in Revenue in Latest Fiscal Quarter Ending June 30, 2023

Atara Biotherapeutics Inc, a renowned biotechnology and pharmaceuticals company, recently announced its financial results for the most recent fiscal period, and the numbers were very disappointing. The company witnessed a drastic decline in revenue, which faded by a staggering -93.003% to a mere $3.61 million. Furthermore, its shortfall per share expanded from -$0.72 in the prior reporting period to -$0.68 in the current period, indicating a worsening financial situation.
Comparing the recent reporting period to the same period last year, the company's revenue fell by -15.162% from $4.25 million. This significant decline in revenue raises concerns about the company's financial performance and its ability to generate sufficient income to cover its expenses.






 

Atara Biotherapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com